Tesamorelin

What Is Tesamorelin?

Tesamorelin is a synthetic analog of the full 44-amino-acid GHRH molecule, modified specifically to resist the enzymes that would otherwise break it down quickly in the body. Unlike sermorelin, which uses only the shortened, active portion of GHRH, tesamorelin retains the complete sequence with a stabilizing modification added.

Tesamorelin holds a distinct place among GHRH-related compounds: it's the only one with current FDA approval for a specific indication, reducing excess visceral abdominal fat in adults with HIV-associated lipodystrophy. That approval, granted in 2010 and updated with a new formulation in 2025, rests on large, well-documented Phase 3 clinical trials rather than the animal or small-scale human studies that back most compounds in this space.

What Tesamorelin Is Being Researched For

• Visceral Fat Reduction in HIV-Associated Lipodystrophy

  The core evidence for tesamorelin comes from its approved indication. A pivotal Phase 3 trial in 412 adults with HIV-associated abdominal fat accumulation found a significant reduction in visceral adipose tissue compared to placebo over 26 weeks.^[1]

• Confirming the Effect Across a Larger Population

  A pooled analysis combining two large Phase 3 trials, totaling more than 800 participants, confirmed a consistent reduction in visceral fat with tesamorelin treatment, reinforcing the original trial's findings at a larger scale.^[2]

• Metabolic Effects Beyond Fat Reduction

  Beyond the fat reduction itself, research has examined whether that change in visceral fat translates into broader metabolic improvements, finding that reduced visceral adiposity was associated with a more favorable metabolic profile in treated patients.^[3]

How Tesamorelin Works

• Stimulating Growth Hormone Release

  Research points to tesamorelin binding to GHRH receptors in the pituitary gland, triggering the same pulsatile growth hormone release pathway the body's natural GHRH uses, which in turn raises IGF-1 levels.^[1]

• Directing Fat Loss Preferentially to Visceral Fat

  Research points to the resulting rise in growth hormone and IGF-1 driving fat breakdown that's directed specifically at visceral fat, the fat surrounding internal organs, rather than subcutaneous fat or overall body weight. This selectivity is tied to visceral fat tissue having a higher density of growth hormone receptors.^[1][2]

• A Short-Acting Signal That Preserves Pulsatility

  Research points to tesamorelin's short half-life producing a discrete growth hormone pulse rather than a sustained elevation, which is thought to help preserve the body's natural pulsatile release pattern rather than overriding it.

Reconstitution and Handling

Tesamorelin is available as an FDA-approved pharmaceutical product administered under clinical supervision, but research-grade vials sold as lyophilized powder are also common and require reconstitution with bacteriostatic water before use. Water should be added slowly rather than injected directly into the powder, and the vial should be swirled, not shaken.

Since the amount of water used affects the concentration of the final solution, researchers often use a dosage calculator to work this out before mixing. Once reconstituted, the solution is kept refrigerated to help preserve its stability.

Key Takeaways

Tesamorelin stands out as the only GHRH analog with a current, active FDA approval, backed by large Phase 3 trials rather than the smaller or animal-only studies typical of most compounds on this site. Its defining mechanistic feature is selectivity for visceral fat specifically, tied to that tissue's higher density of growth hormone receptors. The approval remains narrow, specifically for HIV-associated lipodystrophy, so research and use outside that population is considered off-label.

Frequently Asked Questions

Sources and Research

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359-2370.
2. Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with a safety extension phase. J Clin Endocrinol Metab. 2010;95(9):4291-4304.
3. Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clin Infect Dis. 2012;54(11):1642-1651.